{"id":"NCT00363896","sponsor":"AstraZeneca","briefTitle":"A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-08-15","resultsPosted":"2012-11-01","lastUpdate":"2017-01-06"},"enrollment":843,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Aclidinium bromide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aclidinium 200 μg once-daily","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.","primaryOutcome":{"measure":"Trough FEV1 (L) at 28 Weeks on Treatment","timeFrame":"Week 28","effectByArm":[{"arm":"Aclidinium 200 μg Once-daily","deltaMin":1.422,"sd":0.011},{"arm":"Placebo","deltaMin":1.356,"sd":0.017}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":132,"countries":["Andorra","Austria","Belgium","Bulgaria","Czechia","Denmark","France","Germany","Hungary","Italy","Netherlands","Poland","Romania","Russia","Spain","United Kingdom"]},"refs":{"pmids":["21518460"],"seeAlso":["http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4056&filename=Synopsis_m-34273-30.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":627},"commonTop":["Nasopharyngitis","Headache","Back pain","Cough"]}}